Establishing a common language for the stakeholders in stratified medicine — including drug developers, diagnostic companies, regulators and payers — could help tackle the complex challenges posed by biomarker-based drug development.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Hughes, B. Developing tools for stratified medicine. Nat Rev Drug Discov 8, 919–920 (2009). https://doi.org/10.1038/nrd3070
Issue Date:
DOI: https://doi.org/10.1038/nrd3070
This article is cited by
-
Quantifying factors for the success of stratified medicine
Nature Reviews Drug Discovery (2011)